 | • レポートコード：GIR-22F19143 • 出版社/出版日：GlobalInfoResearch / 2022年11月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Antidiabetic Glucagon-like Peptide 1 Agonists Market 2022」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社の最新の調査によると、世界の抗糖尿病グルカゴン様ペプチド1アゴニストの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 抗糖尿病グルカゴン様ペプチド1アゴニスト市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次をカバーします。 ・エクセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド アプリケーション別セグメントは次のように区分されます。 ・病院、薬局 世界の抗糖尿病グルカゴン様ペプチド1アゴニスト市場の主要な市場プレーヤーは以下のとおりです。 ・Novo Nordisk、AstraZeneca、Eli Lily、GSK、Sanofi、Bristol-Myers Squibb 地域別セグメントは次の地域・国をカバーします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、抗糖尿病グルカゴン様ペプチド1アゴニスト製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な抗糖尿病グルカゴン様ペプチド1アゴニストメーカーの企業概要、2019年～2022年までの抗糖尿病グルカゴン様ペプチド1アゴニストの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な抗糖尿病グルカゴン様ペプチド1アゴニストメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別抗糖尿病グルカゴン様ペプチド1アゴニストの販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの抗糖尿病グルカゴン様ペプチド1アゴニストのタイプ別とアプリケーション別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での抗糖尿病グルカゴン様ペプチド1アゴニスト市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および抗糖尿病グルカゴン様ペプチド1アゴニストの産業チェーンを掲載しています。 ・第13、14、15章では、抗糖尿病グルカゴン様ペプチド1アゴニストの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 抗糖尿病グルカゴン様ペプチド1アゴニストの概要 - タイプ別分析（2017年vs2021年vs2028年）：エクセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド - アプリケーション別分析（2017年vs2021年vs2028年）：病院、薬局 - 世界の抗糖尿病グルカゴン様ペプチド1アゴニスト市場規模・予測 - 世界の抗糖尿病グルカゴン様ペプチド1アゴニスト生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Novo Nordisk、AstraZeneca、Eli Lily、GSK、Sanofi、Bristol-Myers Squibb ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：エクセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド ・アプリケーション別分析2017年-2028年：病院、薬局 ・抗糖尿病グルカゴン様ペプチド1アゴニストの北米市場分析 - 抗糖尿病グルカゴン様ペプチド1アゴニストの北米市場：タイプ別市場規模2017年-2028年 - 抗糖尿病グルカゴン様ペプチド1アゴニストの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・抗糖尿病グルカゴン様ペプチド1アゴニストのヨーロッパ市場分析 - ：抗糖尿病グルカゴン様ペプチド1アゴニストのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：抗糖尿病グルカゴン様ペプチド1アゴニストのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・抗糖尿病グルカゴン様ペプチド1アゴニストのアジア太平洋市場分析 - 抗糖尿病グルカゴン様ペプチド1アゴニストのアジア太平洋市場：タイプ別市場規模2017年-2028年 - 抗糖尿病グルカゴン様ペプチド1アゴニストのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・抗糖尿病グルカゴン様ペプチド1アゴニストの南米市場分析 - 抗糖尿病グルカゴン様ペプチド1アゴニストの南米市場：タイプ別市場規模2017年-2028年 - 抗糖尿病グルカゴン様ペプチド1アゴニストの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・抗糖尿病グルカゴン様ペプチド1アゴニストの中東・アフリカ市場分析 - 抗糖尿病グルカゴン様ペプチド1アゴニストの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 抗糖尿病グルカゴン様ペプチド1アゴニストの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Antidiabetic Glucagon-like Peptide 1 Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Antidiabetic Glucagon-like Peptide 1 Agonists market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Antidiabetic Glucagon-like Peptide 1 Agonists global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Exenatied segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists include Novo Nordisk, AstraZeneca, Eli Lily, GSK, and Sanofi, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Antidiabetic Glucagon-like Peptide 1 Agonists market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market segment by Application can be divided into
Hospital
Pharmacy
The key market players for global Antidiabetic Glucagon-like Peptide 1 Agonists market are listed below:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antidiabetic Glucagon-like Peptide 1 Agonists product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, with price, sales, revenue and global market share of Antidiabetic Glucagon-like Peptide 1 Agonists from 2019 to 2022.
Chapter 3, the Antidiabetic Glucagon-like Peptide 1 Agonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antidiabetic Glucagon-like Peptide 1 Agonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Antidiabetic Glucagon-like Peptide 1 Agonists market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antidiabetic Glucagon-like Peptide 1 Agonists.
Chapter 13, 14, and 15, to describe Antidiabetic Glucagon-like Peptide 1 Agonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Antidiabetic Glucagon-like Peptide 1 Agonists Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Market Analysis by Application
1.3.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size & Forecast
1.4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume (2017-2028)
1.4.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (2017-2028)
1.5 Global Antidiabetic Glucagon-like Peptide 1 Agonists Production Capacity Analysis
1.5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Total Production Capacity (2017-2028)
1.5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
1.6.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
1.6.3 Antidiabetic Glucagon-like Peptide 1 Agonists Trends Analysis
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Eli Lily
2.3.1 Eli Lily Details
2.3.2 Eli Lily Major Business
2.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Sanofi
2.5.1 Sanofi Details
2.5.2 Sanofi Major Business
2.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Bristol-Myers Squibb
2.6.1 Bristol-Myers Squibb Details
2.6.2 Bristol-Myers Squibb Major Business
2.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Antidiabetic Glucagon-like Peptide 1 Agonists Breakdown Data by Manufacturer
3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Antidiabetic Glucagon-like Peptide 1 Agonists
3.4 Market Concentration Rate
3.4.1 Top 3 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2021
3.4.2 Top 6 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2021
3.5 Global Antidiabetic Glucagon-like Peptide 1 Agonists Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Antidiabetic Glucagon-like Peptide 1 Agonists Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
4.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Region (2017-2028)
4.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2017-2028)
4.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (2017-2028)
4.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (2017-2028)
4.4 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (2017-2028)
4.5 South America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (2017-2028)
4.6 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Type (2017-2028)
5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Type (2017-2028)
5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Application (2017-2028)
6.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Application (2017-2028)
6.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2017-2028)
7.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2017-2028)
7.3 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
7.3.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2017-2028)
7.3.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2017-2028)
8.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2017-2028)
8.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
8.3.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2017-2028)
8.3.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2017-2028)
9.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2017-2028)
9.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
9.3.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2017-2028)
10.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2017-2028)
10.3 South America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
10.3.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2017-2028)
10.3.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2017-2028)
11.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2017-2028)
11.3 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
11.3.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Antidiabetic Glucagon-like Peptide 1 Agonists and Key Manufacturers
12.2 Manufacturing Costs Percentage of Antidiabetic Glucagon-like Peptide 1 Agonists
12.3 Antidiabetic Glucagon-like Peptide 1 Agonists Production Process
12.4 Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
13.3 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer